About Cerebellar degeneration-related protein 2-like
Cerebellar degeneration-related protein 2-like (CDR2L) is a protein
from Homo sapiens identified by UniProt accession
Q86X02, 465 residues long.
MolForge cross-references it against 0 known binders and
17 disease associations.
Target properties
| Protein name | Cerebellar degeneration-related protein 2-like |
| UniProt accession | Q86X02 |
| Gene | CDR2L |
| Organism | Homo sapiens |
| Length | 465 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (17)
Diseases linked to this target (Open Targets).
- hepatocellular carcinoma · score 0.03
- neutrophil percentage of leukocytes · score 0.03
- lymphocyte percentage of leukocytes · score 0.02
- cancer · score 0.02
- neoplasm · score 0.02
- Tetralogy of Fallot · score 0.01
- ulcerative colitis · score 0.01
- calf circumference measurement · score 0.01
- astrocytoma · score 0.00
- Crohn's disease · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86X02-F1 | alphafold | PREDICTED | 73.09 | — |
Amino-acid sequence (465 residues)
MRRAAGMEDF SAEEEESWYD QQDLEQDLHL AAELGKTLLE RNKELEGSLQ QMYSTNEEQV QEIEYLTKQL DTLRHVNEQH AKVYEQLDLT ARDLELTNHR LVLESKAAQQ KIHGLTETIE RLQAQVEELQ AQVEQLRGLE QLRVLREKRE RRRTIHTFPC LKELCTSPRC KDAFRLHSSS LELGPRPLEQ ENERLQTLVG ALRSQVSQER QRKERAEREY TAVLQEYSEL ERQLCEMEAC RLRVQELEAE LLELQQMKQA KTYLLGPDDH LAEALLAPLT QAPEADDPQP GRGDDLGAQD GVSSPAASPG HVVRKSCSDT ALNAIVAKDP ASRHAGNLTL HANSVRKRGM SILREVDEQY HALLEKYEEL LSKCRQHGAG VRHAGVQTSR PISRDSSWRD LRGGEEGQGE VKAGEKSLSQ HVEAVDKRLE QSQPEYKALF KEIFSRIQKT KADINATKVK THSSK
Explore Cerebellar degeneration-related protein 2-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets